



University of Pittsburgh

Managed Financial Conflicts of Interest (FCOI) with Research Funded by the Public Health Service (PHS)

Current as of March 23, 2018

1.

Date Disclosed: April 22, 2013

Investigator with FCOI: William Federspiel, Ph.D.

Title: Professor of Chemical Engineering, Surgery and Bioengineering

PHS Funding: NIH 1 RO 1HL117637-01 *Paracorporeal Ambulatory Assist Lung*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: ALung Technologies, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh; consulting; reimbursed/sponsored travel; equity interest

Approximate dollar value of the SFI: Consulting income and reimbursed/sponsored travel between \$20,000 – \$39,000; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

2.

Date Disclosed: August 19, 2013

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

3.

Date Disclosed: August 19, 2013

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

4.

Date Disclosed: July 31, 2014

Investigator with FCOI: Stephen H. Thorne, Ph.D.

Title: Assistant Professor of Cell Biology

PHS Funding: NIH 1 R01 CA178766-01A1 *Creation of Immuno-Oncolytic Viruses for Cancer Therapy*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Western Oncolytics

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Western Oncolytics; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

5.

Date Disclosed: February 17, 2015

Investigator with FCOI: Lee M. Ritterband, Ph.D.

Title: Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia

PHS Funding: NIH 4 UH 3HL125103-01 *Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

6.

Date Disclosed: March 20, 2015

Investigator with FCOI: Mark H. Yazer, M.D.

Title: Professor of Pathology

PHS Funding: NIH HHSN 268201100004 *Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Octapharma

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$5,000 – \$9,999

7. FCOI eliminated January 16, 2018

Date Disclosed: April 7, 2015

Investigator with FCOI: Michael J. Palladino, PhD

Title: Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1R01GM108073-01A1 *Pre-clinical Studies of Novel Mitochondrial Gene Therapies*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

8. FCOI eliminated May 10, 2016

Date Disclosed: April 15, 2015

Investigator with FCOI: Michael J. Caterina, M.D., Ph.D.

Title: Professor of Neurosurgery, Biological Chemistry and Neuroscience, Johns Hopkins University

PHS Funding: NIH 5 R37DK054824-15 *Nitric Oxide in Bladder Neural-Epithelial Signaling*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Johns Hopkins University

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Johns Hopkins University and licensed to Merck

Approximate dollar value of the SFI: \$40,000 - \$59,999

9. FCOI eliminated December 29, 2015

Date Disclosed: April 29, 2015

Investigator with FCOI: Mary Rothstein

Title: Research Specialist, University of Pittsburgh Cancer Institute

PHS Funding: HHSN 261201400043C *Failed Tubulin Inhibitor Reformulated as Localized Adjuvant Therapy for Head and Neck Cancer*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Qrono, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Qrono, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

10.

Date Disclosed: April 30, 2015

Investigator with FCOI: Louis D. Faló, Jr., M.D., Ph.D.

Title: Professor and Chair of Dermatology

PHS Funding: 5 P50 CA121973-07 (Sub-project ID: 7388) *SPORE in Skin Cancer*

Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

11.

Date Disclosed: April 30, 2015

Investigator with FCOI: Louis D. Falco, Jr., M.D., Ph.D.

Title: Professor and Chair of Dermatology

PHS Funding: 5 R01 EB012776-04 *Fabrication and Characterization of Dissolvable Microneedle Arrays*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

12. FCOI eliminated March 24, 2016

Date Disclosed: May 5, 2015

Investigator with FCOI: Chester Mathis, Ph.D.

Title: Professor of Radiology

PHS Funding: 3 U01 AG024904-10 *Alzheimer's Disease Neuroimaging Initiative*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare

Approximate dollar value of the SFI: \$20,000 - \$39,999

13.

Date Disclosed: May 14, 2015

Investigator with FCOI: Saul Shiffman, Ph.D.

Title: Professor of Psychology

PHS Funding: NIH 5 R01 DA034629-02 *Cessation in Non-Daily Smokers: a RCT of NRT with Ecological Momentary Assessment*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Reynolds American, Inc.; Nicovum (a subsidiary of Reynolds American, Inc.); JSR, LLC

Nature of the SFI: Consulting with Reynolds American and Nicovum; intellectual property rights (e.g., royalties, patents, copyrights) assigned to JSR; equity interest in JSR

Approximate dollar value of the SFI: Consulting income between \$600,000 - \$649,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

14. FCOI eliminated March 24, 2016

Date Disclosed: May 27, 2015

Investigator with FCOI: Chester Mathis, Ph.D.

Title: Professor of Radiology

PHS Funding: NIH 5 P50 AG005133-30 (Sub-Project ID: 6967) *Natural History of Amyloid Deposition Familial Ad*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare

Approximate dollar value of the SFI: \$20,000 - \$39,999

15.

Date Disclosed: May 28, 2015

Investigator with FCOI: Steven Woodcock, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH R01 AT006822 *Formation of omega 3-derived electrophiles during inflammation*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

16.

Date Disclosed: May 28, 2015

Investigator with FCOI: Steven Woodcock, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH R37 HL058115 *Redox transduction of nitric oxide signaling*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

17.

Date Disclosed: May 28, 2015

Investigator with FCOI: Chen-Shan (Julia) Woodcock, M.S.

Title: Graduate Student Researcher, Department of Pharmacology & Chemical Biology

PHS Funding: NIH R37 HL058115 *Redox transduction of nitric oxide signaling*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

18.

Date Disclosed: May 28, 2015
Investigator with FCOI: Chen-Shan (Julia) Woodcock, M.S.
Title: Graduate Student Researcher, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 *Redox-Derived Pulmonary Anti-Inflammatory Mediators*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

19.

Date Disclosed: May 28, 2015
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 *Redox-Derived Pulmonary Anti-Inflammatory Mediators*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

20.

Date Disclosed: May 28, 2015
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH R01 AT006822 *Formation of omega 3-derived electrophiles during inflammation*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

21.

Date Disclosed: May 28, 2015
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH R37 HL058115 *Redox transduction of nitric oxide signaling*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

22. *FCOI eliminated April 26, 2017*

Date Disclosed: June 23, 2015
Investigator with FCOI: Brian Suffoletto, M.D.
Title: Assistant Professor of Emergency Medicine
PHS Funding: NIH 5 K23 AA023284-02 *A Text-Message Intervention to Reduce Alcohol Use Among Young Adult ED Patients*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

23.

Date Disclosed: July 31, 2015
Investigator with FCOI: Brian Suffoletto, M.D.
Title: Assistant Professor of Emergency Medicine
PHS Funding: NIH R34 AA023047 *Brief Alcohol Screening and Intervention for Community College Students (BASICCS)*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

24.

Date Disclosed: August 11, 2015
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH R01 HL064937 *Redox-Derived Pulmonary Anti-Inflammatory Mediators*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

25.

Date Disclosed: August 11, 2015

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH P01 HL103455 *Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

26.

Date Disclosed: August 11, 2015

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH R01 AT006822 *Formation of omega 3-derived electrophiles during inflammation*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

27.

Date Disclosed: August 11, 2015

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH R01 DK071085 *Roles of Nitric Oxide and Superoxide in Cystitis*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

28.

Date Disclosed: August 11, 2015

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH R37 HL058115 *Redox transduction of nitric oxide signaling*

Role on Research Project: Principal Investigator of animal, and Co-Investigator of bench and human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

29. FCOI eliminated September 1, 2016

Date Disclosed: August 11, 2015

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

30.

Date Disclosed: August 13, 2015

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R01 AR066548-01A1 *The Immunoregulatory Effects of Electrophilic Fatty acids on Psoriasis*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

31.

Date Disclosed: August 18, 2015

Investigator with FCOI: Mark Gladwin, M.D.

Title: Professor and Chair of Medicine

PHS Funding: NIH 1 K23 HL124051-01A1 *Nitrite Modulation of Hypertension, Platelet Activation and Mitochondrial Function*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics

Approximate dollar value of the SFI: \$1 - \$4,999

32. FCOI eliminated March 24, 2016

Date Disclosed: October 1, 2015

Investigator with FCOI: Chester Mathis, Ph.D.

Title: Professor of Radiology

PHS Funding: NIH 1 K23 AG049945-01A1 *The Aging Brain and the Cognition-Mobility Interface in Clinically Normal Older Adults*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare

Approximate dollar value of the SFI: \$20,000 - \$39,999

33. FCOI eliminated March 24, 2016

Date Disclosed: October 1, 2015

Investigator with FCOI: William Klunk, M.D., Ph.D.

Title: Professor of Psychiatry and Neurology

PHS Funding: NIH 1 K23 AG049945-01A1 *The Aging Brain and the Cognition-Mobility Interface in Clinically Normal Older Adults*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to GE Healthcare

Approximate dollar value of the SFI: \$20,000 - \$39,999

34. FCOI eliminated August 25, 2016

Date Disclosed: February 3, 2016

Investigator with FCOI: Fuchiang (Rich) Tsui, Ph.D.

Title: Research Assistant Professor of Biomedical Informatics

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Vervtality

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

35. FCOI eliminated April 26, 2017

Date Disclosed: February 8, 2016

Investigator with FCOI: James Eles

Title: Graduate Student, Department of Bioengineering

PHS Funding: NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

36. FCOI eliminated April 26, 2017

Date Disclosed: February 8, 2016

Investigator with FCOI: Xinyan (Tracy) Cui

Title: Professor of Bioengineering

PHS Funding: NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

37. FCOI eliminated July 14, 2017

Date Disclosed: February 12, 2016

Investigator with FCOI: Edward Prochownik, M.D., Ph.D.

Title: Professor of Pediatrics and Microbiology & Molecular Genetics

PHS Funding: NIH 1 U54 CA199092-01 *Center for Multiple Myeloma Nanotherapy*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

38.

Date Disclosed: February 22, 2016

Investigator with FCOI: Andrew Hinck, Ph.D.

Title: Visiting Professor of Structural Biology

PHS Funding: NIH R01 CA172886 *Inhibition of the Tumor-Promoting Effects of TGF-Beta in Advanced Prostate Cancer*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Texas Health Science Center at San Antonio

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Texas Health Science Center at San Antonio

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

39.

Date Disclosed: April 25, 2016

Investigator with FCOI: Rebecca Jacobson, M.D., M.S.

Title: Professor of Biomedical Informatics and Pathology

PHS Funding: NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: NEXI

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

40.

Date Disclosed: April 25, 2016

Investigator with FCOI: Girish Chavan

Title: Staff, Department of Biomedical Informatics

PHS Funding: NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: NEXI

Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

41.

Date Disclosed: April 25, 2016

Investigator with FCOI: Eugene Tseytlin

Title: Staff, Department of Biomedical Informatics

PHS Funding: NIH U24 CA180921 *Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: NEXI

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

42.

Date Disclosed: May 16, 2016

Investigator with FCOI: Dario Vitturi, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH U01 HL117721 *Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

43.

Date Disclosed: June 9, 2016

Investigator with FCOI: Joseph Glorioso, Ph.D.

Title: Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

44.

Date Disclosed: June 9, 2016

Investigator with FCOI: Paola Grandi, Ph.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

45.

Date Disclosed: June 9, 2016

Investigator with FCOI: Justus Cohen, Ph.D.

Title: Research Instructor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncofurus

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

46.

Date Disclosed: June 9, 2016

Investigator with FCOI: William Goins, Ph.D.

Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncofurus

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

47.

Date Disclosed: June 9, 2016

Investigator with FCOI: Nduka Amankolor, M.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncofurus

Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncofurus

Approximate dollar value of the SFI: Consulting income between \$5,000 - \$9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

48.

Date Disclosed: June 13, 2016

Investigator with FCOI: Paola Grandi, Ph.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$100,000 - \$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

49.

Date Disclosed: June 13, 2016

Investigator with FCOI: William Goins, Ph.D.

Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

50.

Date Disclosed: June 13, 2016

Investigator with FCOI: Nduka Amankulor, M.D.

Title: Assistant Professor, Department of Neurological Surgery

PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

Approximate dollar value of the SFI: Consulting income between \$5,000 - \$9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

51. *FCOI eliminated October 3, 2016*

Date Disclosed: June 28, 2016

Investigator with FCOI: Michael McClincy, M.D.

Title: Fellow, Massachusetts General Hospital

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

52.

Date Disclosed: June 28, 2016

Investigator with FCOI: Kevin Bell, Ph.D.

Title: Research Assistant Professor, Department of Orthopaedic Surgery

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

53. *FCOI eliminated August 25, 2016*

Date Disclosed: June 28, 2016

Investigator with FCOI: Robert Hartman, Ph.D.

Title: Postdoctoral Associate, Department of Physical Medicine & Rehabilitation

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

54. *FCOI eliminated September 2, 2016*

Date Disclosed: June 28, 2016

Investigator with FCOI: Xinyan (Tracy) Cui

Title: Professor of Bioengineering

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

55. FCOI eliminated September 2, 2016

Date Disclosed: June 28, 2016

Investigator with FCOI: James Eles

Title: Graduate Student, Department of Bioengineering

PHS Funding: NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

56. FCOI eliminated July 19, 2017

Date Disclosed: July 1, 2016

Investigator with FCOI: Joel S. Greenberger, M.D.

Title: Professor and Chair of Radiation Oncology

PHS Funding: NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

57. FCOI eliminated July 19, 2017

Date Disclosed: July 1, 2016

Investigator with FCOI: Michael W. Epperly, Ph.D.

Title: Associate Professor of Radiation Oncology

PHS Funding: NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

58. FCOI eliminated August 4, 2017

Date Disclosed: July 5, 2016

Investigator with FCOI: Shivalingappa Swamynathan, Ph.D.

Title: Associate Professor of Ophthalmology and Cell Biology

PHS Funding: NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

59. FCOI eliminated August 4, 2017

Date Disclosed: July 5, 2016

Investigator with FCOI: Sudha Swamynathan

Title: Research Technician, Department of Ophthalmology

PHS Funding: NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

60.

Date Disclosed: July 13, 2016

Investigator with FCOI: Yuri Nikiforov, M.D., Ph.D.

Title: Professor of Pathology

PHS Funding: NIH 2 P50 CA097190-11 *Head and Neck Cancer SPORE*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to UPMC

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

61.

Date Disclosed: July 14, 2016

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

62.

Date Disclosed: July 14, 2016

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R21 AI122071-01A1 *The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology*

Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

63.

Date Disclosed: August 9, 2016

Investigator with FCOI: Dario A. Vignali, Ph.D.

Title: Professor and Vice Chair of Immunology

PHS Funding: NIH 9 R01 CA203689-07A1 *Interleukin-35 and the Tumor Microenvironment*

Role on Research Project: Principal Investigator of bench, and Co-Investigator on non-bench, research

Name of Entity in which Significant Financial Interest (SFI) is held: Tizona Therapeutics

Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the St. Jude Children's Research Hospital and licensed to Tizona Therapeutics;

Approximate dollar value of the SFI: Consulting income between \$80,000 - \$99,999; licensing proceeds from intellectual property rights between \$40,000 - \$59,999; equity interest is SFI whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

64.

Date Disclosed: August 23, 2016

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

Role on Research Project: Primary Mentor

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

65.

Date Disclosed: August 23, 2016

Investigator with FCOI: Dario Vitturi, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

66.

Date Disclosed: August 23, 2016

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 1 K01 HL133331-01 *Protection against sickle cell disease nephropathy by nitrated fatty acids*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest; Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

67.

Date Disclosed: September 1, 2016

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

Role on Research Project: Principal Investigator of animal, and Co-Investigator of bench and human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

68.

Date Disclosed: September 1, 2016

Investigator with FCOI: Bruce Freeman, Ph.D.

Title: Professor and Chair of Pharmacology and Chemical Biology

PHS Funding: NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

69.

Date Disclosed: September 1, 2016

Investigator with FCOI: Steven Woodcock, Ph.D.

Title: Research Instructor, Department of Pharmacology & Chemical Biology

PHS Funding: NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

70.

Date Disclosed: September 19, 2016

Investigator with FCOI: Mark Gladwin, M.D.

Title: Professor and Chair of Medicine

PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics
Approximate dollar value of the SFI: \$1 - \$4,999

71.

Date Disclosed: September 19, 2016
Investigator with FCOI: Bruce Freeman, Ph.D.
Title: Professor and Chair of Pharmacology and Chemical Biology
PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*
Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

72.

Date Disclosed: September 19, 2016
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*
Role on Research Project: Principal Investigator of animal, and Co-Investigator of bench and human subject, research
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

73.

Date Disclosed: September 19, 2016
Investigator with FCOI: Steven Woodcock, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: \$10,000 - \$19,999

74. FCOI eliminated March 20, 2018

Date Disclosed: September 23, 2016

Investigator with FCOI: Matthew Neal, M.D.

Title: Assistant Professor of Surgery and Critical Care Medicine

PHS Funding: NIH 1 R35 GM119526-01 *Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After Trauma*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

75. FCOI eliminated March 29, 2017

Date Disclosed: September 23, 2016

Investigator with FCOI: Brian Suffoletto, M.D.

Title: Assistant Professor of Emergency Medicine

PHS Funding: NIH 1 R01 AA23650-01A1 *Mechanisms of Change for an Effective Alcohol Text Message Intervention*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

76.

Date Disclosed: September 27, 2016

Investigator with FCOI: Patricia Opresko, Ph.D.

Title: Associate Professor of Environmental and Occupational Health

PHS Funding: NIH 2 R44 GM108187-03 *GammaPNA Miniprobos for Telomere Analysis and RNA FISH*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to PNA Innovations, Inc.

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

77.

Date Disclosed: October 5, 2016

Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.

Title: Research Assistant Professor of Pharmacology & Chemical Biology

PHS Funding: NIH 1 U54 DK112079-01 *University of Pittsburgh O'Brien Cooperative Research Center Program*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

78.

Date Disclosed: October 10, 2016

Investigator with FCOI: Guergana Savova, Ph.D.

Title: Associate Professor of Pediatrics, Harvard Medical School and Computational Health Informatics Program at Boston Children's Hospital

PHS Funding: NIH 5 U24 CA184407-03 *Cancer Deep Phenotype Extraction from Electronic Medical Records*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Wired Informatics, LLC

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

79.

Date Disclosed: October 18, 2016

Investigator with FCOI: John Kellum, M.D.

Title: Professor and Vice Chair for Research, Department of Critical Care Medicine

PHS Funding: NIH 1 R01 DK106256-01A1 *Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Astute Medical

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

80. FCOI eliminated July 19, 2017

Date Disclosed: October 25, 2016

Investigator with FCOI: Alexander Deiters, Ph.D.

Title: Professor of Chemistry

PHS Funding: NIH 1 R21 HD 85206-01A1 *Optical Control of Translation and Gene Editing in Zebrafish Embryos*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: North Carolina State University

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to North Carolina State University

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

81.

Date Disclosed: October 26, 2016

Investigator with FCOI: Bonnie Hall, Ph.D.

Title: Research Instructor, Department of Microbiology & Molecular Genetics

PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

82.

Date Disclosed: November 2, 2016

Investigator with FCOI: Mary Loghmani, P.T., Ph.D.

Title: Associate Professor of Physical Therapy, Indiana University

PHS Funding: NIH 5 P2C HD086843-02 *Alliance for Regenerative Rehabilitation Research & Training (AR3T)*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Health Smart Technologies, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

83. FCOI eliminated March 3, 2018

Date Disclosed: November 17, 2016

Investigator with FCOI: Maliha Zahid, M.D., Ph.D.

Title: Research Instructor, Department of Developmental Biology

PHS Funding: NIH 1 UL1 TR 001857-01 *University of Pittsburgh Clinical and Translational Science Institute*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

84.

Date Disclosed: January 4, 2017

Investigator with FCOI: Lee M. Ritterband, Ph.D.

Title: Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia

PHS Funding: NIH 1 R03 HL135213-01 *Feasibility and Acceptability of an internet-based cognitive-behavioral treatment for insomnia in adults with asthma*

Role on Research Project: Consultant

Name of Entity in which Significant Financial Interest (SFI) is held: BeHealth Solutions, LLC

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

85.

Date Disclosed: January 17, 2017

Investigator with FCOI: Yadong Wang, Ph.D.

Title: Professor, Department of Bioengineering

PHS Funding: NIH 7 R21 EB016774-03 *Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair*

Role on Research Project: Principal Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

86.

Date Disclosed: March 2, 2017

Investigator with FCOI: Kenneth W. Kinzler, PhD

Title: Professor of Oncology, Johns Hopkins University

PHS Funding: NIH 2 U01 CA152753-06 *ctDNA for the Early Detection and Monitoring of Colorectal Cancer*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Sysmex Corporation
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University and licensed to Sysmex Corporation; payment for services
Approximate dollar value of the SFI: Intellectual property royalty distributions between \$60,000 - \$79,999; payment for services between \$60,000-\$79,999

87.

Date Disclosed: June 21, 2017
Investigator with FCOI: Joseph Glorioso, PhD
Title: Professor of Microbiology & Molecular Genetics
PHS Funding: NIH 5 R01 CA175052-04 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*
Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
Approximate dollar value of the SFI: Consulting income between \$100,000-\$149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

88.

Date Disclosed: July 26, 2017
Investigator with FCOI: Beibei Bill Chen, PhD
Title: Associate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine
PHS Funding: NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Koutif Therapeutics
Nature of the SFI: equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics
Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interests are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

89.

Date Disclosed: July 26, 2017
Investigator with FCOI: Rama K. Mallampalli, MD
Title: Division Chief, Division of Pulmonary, Allergy, and Critical Care Medicine
PHS Funding: NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*
Role on Research Project: Principal Investigator of bench, and Co-Investigator of animal, research
Name of the Entity in which Significant Financial Interest (SFI) is held: Koutif Therapeutics

Nature of the SFI: equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

90.

Date Disclosed: July 26, 2017

Investigator with FCOI: Xiang-Qun (Sean) Xie, PhD, EMBA

Title: Associate Dean for Research Innovation and Professor, Department of Pharmaceutical Sciences

PHS Funding: NIH 1 R44 CA210882 *SQSTM1/P62-Targeted Small Molecules for Multiple Myeloma Disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: ID4Pharma, LLC

Nature of the SFI: equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned/licensed to ID4Pharma

Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

91.

Date Disclosed: August 9, 2017

Investigator with FCOI: John M. Kirkwood, MD

Title: Professor of Medicine, Division of Hematology/Oncology

PHS Funding: NIH 5 U01 CA180820 *ECOG-ACRIN Operations Center*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Novartis

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

92.

Date Disclosed: October 12, 2017

Investigator with FCOI: Steven Moulton, MD

Title: Professor of Surgery, University of Colorado School of Medicine

PHS Funding: NIH 7 UM1 HL120877 *Analysis and Characterization of Trauma-Induced Coagulopathy*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Flashback Technologies, Inc.

Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Colorado and licensed to Flashback Technologies, Inc.; equity interest; consulting; management position

Approximate dollar value of the SFI: Consulting income between \$10,000-\$19,999; intellectual property rights between \$10,000-\$19,999; management position is unpaid; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

93.

Date Disclosed: November 8, 2017

Investigator with FCOI: Francisco Schopfer, Ph.D.

Title: Research Associate Professor of Pharmacology and Chemical Biology

PHS Funding: NIH 5 R01 HL132550 *Anti-Inflammatory Lipid Mediators in Asthma*

Role on Research Project: Co-Investigator

Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: Consulting income between \$20,000 - \$39,999; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

94.

Date Disclosed: November 15, 2017

Investigator with FCOI: Ling Wang, MD, PhD

Title: Research Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

95.

Date Disclosed: November 15, 2017

Investigator with FCOI: Charles F. McTiernan, PhD

Title: Research Associate Professor of Medicine, Division of Cardiology

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

96.

Date Disclosed: November 16, 2017

Investigator with FCOI: Jesus Tejero Bravo, PhD

Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position is unpaid; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

97.

Date Disclosed: November 16, 2017

Investigator with FCOI: Jason J. Rose, MD, MBA

Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position is unpaid; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

98.

Date Disclosed: November 16, 2017

Investigator with FCOI: Mark T. Gladwin, MD

Title: Chair, Department of Medicine

PHS Funding: NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

99.

Date Disclosed: November 20, 2017

Investigator with FCOI: Jesus Tejero Bravo, PhD

Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

PHS Funding: NIH 5 R21 ES027390 *Countermeasure Therapeutics for Acute Lung Injury*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Management position is unpaid; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

100.

Date Disclosed: January 26, 2018

Investigator with FCOI: John Kellum, MD

Title: Professor and Vice Chair for Research, Department of Critical Care Medicine

PHS Funding: NIH 1 R21 DK113486 *Biochemical and Reno-Protective Effects of Remote Ischemic Preconditioning on Contrast-Induced Kidney Disease*

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Astute Medical

Nature of the SFI: Consulting

Approximate dollar value of the SFI: \$10,000 - \$19,999

101.

Date Disclosed: March 5, 2018

Investigator with FCOI: Stephen F. Badylak, DVM, PhD, MD

Title: Professor, Department of Surgery and Deputy Director of the McGowan Institute for Regenerative Medicine

PHS Funding: NIH 5 F31 CA210694 *Understanding Esophageal Adenocarcinoma Progression Using Inflammatory and Neoplastic Extracellular Matrix Hydrogels*

Role on Research Project: Primary Mentor

Name of the Entity in which Significant Financial Interest (SFI) is held: Restoure, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Restoure, Inc.

Approximate dollar value of the SFI: Management position is unpaid; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.